Chat with us, powered by LiveChat Thailand Medical News - PR Releases
PR Releases
Presented by
Source: Roche  Nov 05, 2018
 • The phase III CLL14 study compared Venclexta/Venclyxto in combination with Gazyva/Gazyvaro to standard-of-care Gazyva/Gazyvaro plus chlorambucil  • Data will be submitted to health authorities and presented at an upcoming medical meeting     Basel,1 November 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the randomised phase III CLL14 study, which ...
Source: AstraZeneca  Oct 30, 2018
Data show Lokelma maintained normokalaemia during days 8-29 of the maintenance phase in patients from four Asian countries   AstraZeneca today presented the results from the HARMONIZE Global Phase III trial, which investigated the safety and efficacy of Lokelma (sodium zirconium cyclosilicate) vs. placebo in patients with hyperkalaemia in Japan, Korea, Taiwan and Russia. The resul...
Source: Merck  Oct 30, 2018
Merck Today Announced The 24-Week Results Of The Phase II Study Of Evobrutinib In Patients With Relapsing Multiple Sclerosis (Rms) In Berlin, Germany. Evobrutinib First Bruton’s Tyrosine Kinase inhibitor (BTKi) demonstrating clinical proof-of-concept in relapsing multiple sclerosis (RMS) Study met primary endpoint demonstrating significant reduction in Gd+ enhancing T1 lesions on MRI wi...
Source: Baze  Oct 03, 2018
Lifestyle Brand Introduces Innovative Customized Health Experience to Combat Nutritional Deficiencies SAN FRANCISCO, Oct. 3, 2018 /PRNewswire/ -- Baze, a lifestyle brand focusing on personalized health, has launched the Baze Starter Kit, a simple and affordable, fully-tailored experience designed to combat nutrient deficiencies. The Baze Starter Kit combine...